Document Detail

Myocardial infarction in the 1990s. The importance of early thrombolytic therapy.
MedLine Citation:
PMID:  7753739     Owner:  NLM     Status:  MEDLINE    
Substantial advances in the diagnosis and treatment of ischemic heart disease, especially myocardial infarction, have reduced mortality rates during the past several years. This progress is tempered, however, by the continuing large overall incidence of myocardial infarction and cardiac death in persons in their prime years. Preventive measures are important and are usually best applied by primary care physicians. The acute crisis of coronary artery thrombosis demands accurate diagnosis and timely thrombolytic therapy, which has halved the mortality rate of myocardial infarction. Several effective thrombolytic agents are available; on the basis of several large international trials of these drugs, it appears that the benefits of early and appropriate use of any one of these agents outweigh any individual advantages. In addition to thrombolytics, aspirin and heparin are necessary adjunctive drugs for acute myocardial infarction. Nitroglycerin is helpful, but its essential role seems less evident. Earlier use of beta blockers and angiotensin-converting enzyme inhibitors has been proved effective in reducing mortality. Percutaneous transluminal coronary angioplasty is definitely as effective as thrombolytic therapy, but immediate application is logistically challenging in most US hospitals.
R E Fowles
Related Documents :
1894539 - Clinical management of patients receiving thrombolytic therapy.
7554409 - Left ventricular function following thrombolytic therapy for myocardial infarction.
10073789 - Consultation before thrombolytic therapy in acute myocardial infarction. second nationa...
10172049 - Pharmacoeconomic aspects of treatment of acute myocardial infarction with thrombolytic ...
7605149 - Epidemiology of avoidable delay in the care of patients with acute myocardial infarctio...
6969559 - Corticosteroids in acute myocardial infarction.
18477469 - Inhibition of gsk-3 reduces infarct volume and improves neurobehavioral functions.
23810239 - Diffuse st-elevation following j-wave presentation as an uncommon electrocardiogram pat...
16168189 - Recommended standards for biochemical markers of myocardial damage: all wales clinical ...
Publication Detail:
Type:  Comparative Study; Journal Article; Review    
Journal Detail:
Title:  Postgraduate medicine     Volume:  97     ISSN:  0032-5481     ISO Abbreviation:  Postgrad Med     Publication Date:  1995 May 
Date Detail:
Created Date:  1995-06-16     Completed Date:  1995-06-16     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  0401147     Medline TA:  Postgrad Med     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  135-8, 141-2, 145-6     Citation Subset:  AIM; IM    
Salt Lake Clinic, UT 84102, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-Antagonists / therapeutic use
Angioplasty, Transluminal, Percutaneous Coronary
Aspirin / therapeutic use
Clinical Trials as Topic
Drug Therapy, Combination
Heparin / therapeutic use
Middle Aged
Myocardial Infarction / etiology,  mortality,  therapy*
Nitroglycerin / therapeutic use
Risk Factors
Streptokinase / therapeutic use
Time Factors
Urokinase-Type Plasminogen Activator / therapeutic use
Warfarin / therapeutic use
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 50-78-2/Aspirin; 55-63-0/Nitroglycerin; 81-81-2/Warfarin; 9005-49-6/Heparin; EC 3.4.-/Streptokinase; EC Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Henoch-Schönlein purpura. A multisystem disease also seen in adults.
Next Document:  No ice, no butter. Advice on management of burns for primary care physicians.